2023 CMHC Fellows POST-Survey: Annual Meeting

First and Last Name *

Email *

According to the 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapies, which of the following is an appropriate LDL-C target in a woman with ASCVD, type 2 diabetes and hypertension? *

≥50% LDL-C reduction AND LDL-C <55 mg/dL

≥50% LDL-C reduction OR LDL-C <55 mg/dL

≥50% LDL-C reduction AND LDL-C <70 mg/dL

≥50% LDL-C reduction OR LDL-C <70 mg/dL

≥50% LDL-C reduction AND LDL-C <100 mg/dL

≥50% LDL-C reduction OR LDL-C <100 mg/dL

WHICH OF THE FOLLOWING STATEMENTS IS TRUE ABOUT THE CLEAR OUTCOMES TRIAL WITH BEMPEDOIC ACID? *

It enrolled patients with existing ASCVD

It enrolled patients at-risk for or with existing ASCVD

Significant cardiovascular risk reduction was observed in the primary prevention cohort only

It enrolled patients on high-intensity statin therapy

PARTICIPATING IN THIS ACTIVITY INCREASED MY KNOWLEDGE ABOUT THE MANAGEMENT OF ASCVD RISK AND LIPID LOWERING *

TRUE OR FALSE: ACCORDING TO THE 2022 ACC CONSENSUS STATEMENT ON NON-STATIN THERAPIES FOR LDL-C LOWERING, INCLISIRAN AND A PCSK9 INHIBITOR CAN BE REASONABLY COMBINED TOGETHER IN VERY HIGH-RISK PATIENTS THAT NEED FURTHER LDL-C LOWERING. *

True

False

A 58-YEAR-OLD WOMAN WITH A RECENT MYOCARDIAL INFARCTION AND STENT PLACEMENT TO THE LAD 6 MONTHS AGO HAS BEEN TRIED MULTIPLE STATINS AND HAS SEVERE MYALGIAS WITH HIGH INTENSITY AND MODERATE INTENSITY STATINS. THE PATIENT IS ON A MAXIMALLY TOLERATED DOSE OF STATIN (PRAVASTATIN 20 MG DAILY). EZETIMIBE 10 MG IS THEN ADDED AND LIPID PROFILE REVEALS: TOTAL CHOLESTEROL = 261 MG/DL; TRIGLYCERIDES = 150 MG/DL ; HDL = 40 MG/DL; LDL-C = 175 MG/DL; LP(A) = 200 MG/DL. ACCORDING TO THE 2022 ACC EXPERT DECISION PATHWAY ON NON-STATIN THERAPIES, WHICH OF THE FOLLOWING OPTIONS SHOULD YOU CONSIDER NEXT TO REDUCE THE RISK OF FUTURE CARDIOVASCULAR EVENTS? *

A 38-YEAR-OLD PATIENT WITH A RECENT ACS EVENT, FAMILY HISTORY OF ASCVD, HAS AN ELEVATED LP(A) OF 230 NMOL/L, WHICH WAS MEASURED TO BETTER ASSESS RISK BASED ON PATIENT’S HISTORY. PATIENT IS CURRENTLY ON HIGH INTENSITY STATINS FOR LDL-C LOWERING (CURRENT LDL-C = 115 MG/DL). WHICH OF THE FOLLOWING THERAPIES WOULD YOU RECOMMEND TO ALSO ADDRESS ELEVATED LP(A) AND FURTHER LOWER LDL-C? (SELECT ALL THAT APPLY) *

Further optimize diet & lifestyle

Substitute for another high-intensity statin

Ezetimibe

Bempedoic Acid

PCSK9 inhibitors

Inclisiran

All of the above

ACCORDING TO TRIALS WITH PCSK9 INHIBITORS, WHICH OF THE FOLLOWING IS TRUE ABOUT THE DEGREE OF BENEFIT IN REDUCING CV RISK WITH THESE AGENTS? *

Benefits were relatively equal across enrolled patients

Benefits were greater in patients with high-risk features

Benefits occurred independently of baseline Lp(a) levels

Benefits were greater in patients with lower baseline Lp(a) levels

DO YOU PLAN TO MAKE CHANGES TO PRACTICE AS A RESULT OF INFORMATION RECEIVED DURING THIS MEETING? *

Yes

No

IF YES, WHICH CHANGES DO YOU PLAN TO MAKE AS A RESULT OF INFORMATION PROVIDED IN THIS ACTIVITY? (SELECT ALL THAT APPY) *

Monitor advances in lipid-lowering therapy and emerging data with newer agents

Intensify/add lipid-lowering treatments every 6-12 weeks until LDL-C goal is achieved in all patients

Consider more intensive lipid-lowering therapy for very-high risk patients

Monitor patients for potential statin intolerance or non-adherence to other lipid-lowering therapies

SEVERAL NEW DRUGS OR INDICATIONS HAVE BEEN ADDED FOR THE MANAGEMENT OF PATIENTS WITH CARDIOMETABOLIC DISEASE. WHICH OF THE FOLLOWING RECENTLY-APPROVED DRUGS OR INDICATIONS ARE YOU (OR YOUR PRACTICE) HAVING THE MOST ISSUES WITH PRIOR AUTHORIZATION/PATIENT ACCESS (SELECT ALL THAT APPLY)? *

FOR YOUR PATIENTS WITH ELEVATED LDL-C AND ON MAXIMAL STATIN THERAPY, WHAT IS THE MOST COMMON NON-STATIN AGENT THAT YOU PRESCRIBE FOR FURTHER LDL-C LOWERING? *

Ezetimibe

Bempedoic acid

Bempedoic acid/ezetimibe combination

PCSK9 inhibitor (evolocumab or alirocumab)

Inclisiran

Not applicable to me/currently do not prescribe

Other...

FOR YOUR PATIENTS WITH ELEVATED LDL-C AND ON MAXIMAL STATIN THERAPY, WHAT IS THE MOST COMMON NON-STATIN AGENT THAT YOU PRESCRIBE FOR FURTHER LDL-C LOWERING? Other...

WHAT DO YOU EXPECT TO LEARN (OR HOPE TO ACHIEVE) THROUGHOUT THE COURSE OF THE YEAR FROM CMHC'S EDUCATIONAL PROGRAMS AND THE FELLOWS PROGRAM? *

WHAT ARE SOME OF THE CURRENT CHALLENGES YOU FACE AS A FELLOW IN TRYING TO TAKE CARE OF PATIENTS WITH CARDIOMETABOLIC RISK FACTORS OR CARDIOMETABOLIC DISEASE? *

Please share 3-5 personal learning objectives and what you anticipate learning from attending the 2023 CMHC Annual Meeting. *

PLEASE ADD ANY OTHER COMMENTS: *

You are here